Long COVID prevalence and risk factors in middle- and high-income countries: Secondary Analysis of the multinational Anti-Coronavirus Therapies (ACT) Trials

SUPPLEMENTARY MATERIALS

1

SUPPLEMENTARY 1: Study Symptom Questionnaire

Symptoms and Signs Form for: Day 8, Day 45 and Day 180 Visits			
Question	**Response Choices**	**Data Entry**	**Instructions**
Are there any symptoms at the time of follow-up visit?	No/Yes/Unknown		*(If No or Unknown, hide list of Symptoms and Signs)*
If Yes, Symptoms are related to:	Persistent COVID		
	Confirmed reinfection		
	Suspected reinfection		
	Suspected other causes		
Question	**Response Choices**	**Data Entry**	**Instructions**
Fever (>=38 ºC or 100.4 ºF)	No/Yes		
Cough	No/Yes		
if yes, with sputum	No/Yes		
Muscle pain	No/Yes		
Sore throat	No/Yes		
Shortness of breath on usual activities of daily living	No/Yes		
Loss of sense of smell or taste	No/Yes		
Diarrhea	No/Yes		
Fatigue	No/Yes		
Conjunctivitis	No/Yes		
Headaches	No/Yes		
Sleeping Disorder	No/Yes		
Palpitations	No/Yes		
Concentration impairment	No/Yes		
Memory impairment	No/Yes		
Joint pain	No/Yes		
Other: Specify	No/Yes		

SUPPLEMENTARY 2A-B: Long COVID symptoms in inpatients and outpatients

Supplementary Table 2A – Long COVID symptom prevalence (inpatients only)

	Baseline	Day 8	Day 45	Day 180
Patients with data, N	494	601	702	1119
Covid symptoms				
Muscle pain, n(%)	276 (55.9%)	111 (18.5%)	38 (5.4%)	45 (4.0%)
Shortness of breath on activities of daily living, n(%)	413 (83.6%)	253 (42.1%)	78 (11.1%)	49 (4.4%)
Loss of sense of smell or taste, n(%)	149 (30.2%)	63 (10.5%)	17 (2.4%)	6 (0.5%)
Diarrhoea, n(%)	89 (18.0%)	35 (5.8%)	9 (1.3%)	2 (0.2%)
Fatigue, n(%)	322 (65.2%)	307 (51.1%)	176 (25.1%)	144 (12.9%)
Headaches, n(%)	150 (30.4%)	53 (8.8%)	33 (4.7%)	49 (4.4%)
Sleeping disorder, n(%)	66 (13.4%)	83 (13.8%)	61 (8.7%)	108 (9.7%)
Palpitations, n(%)	49 (9.9%)	36 (6.0%)	23 (3.3%)	15 (1.3%)
Concentration impairment, n(%)	28 (5.7%)	25 (4.2%)	19 (2.7%)	54 (4.8%)
Memory impairment, n(%)	19 (3.8%)	17 (2.8%)	23 (3.3%)	37 (3.3%)
Joint pain, n(%)	79 (16.0%)	53 (8.8%)	59 (8.4%)	92 (8.2%)
Overall				
Any symptoms listed above, n(%)	483 (97.8%)	417 (69.4%)	236 (33.6%)	277 (24.8%)
With only one symptoms, n(%)	81 (16.4%)	145 (24.1%)	89 (12.7%)	107 (9.6%)
With two symptoms, n(%)	84 (17.0%)	104 (17.3%)	64 (9.1%)	70 (6.3%)
With ≥ 3 symptoms , n(%)	318 (64.4%)	168 (28.0%)	83 (11.8%)	100 (8.9%)

Supplementary Table 2B – Long COVID symptom prevalence (outpatients only)

	Baseline	Day 8	Day 45	Day 180
Patients with data, N	2102	2122	2422	3578
Covid symptoms				
Muscle pain, n(%)	1423 (67.7%)	480 (22.6%)	121 (5.0%)	85 (2.4%)
Shortness of breath on activities of daily living, n(%)	653 (31.1%)	363 (17.1%)	99 (4.1%)	77 (2.2%)
Loss of sense of smell or taste, n(%)	1167 (55.5%)	677 (31.9%)	193 (8.0%)	94 (2.6%)
Diarrhoea, n(%)	556 (26.5%)	254 (12.0%)	64 (2.6%)	41 (1.1%)
Fatigue, n(%)	1211 (57.6%)	881 (41.5%)	447 (18.5%)	266 (7.4%)
Headaches, n(%)	1124 (53.5%)	443 (20.9%)	163 (6.7%)	333 (9.3%)
Sleeping disorder, n(%)	638 (30.4%)	561 (26.4%)	388 (16.0%)	493 (13.8%)
Palpitations, n(%)	260 (12.4%)	147 (6.9%)	54 (2.2%)	27 (0.8%)
Concentration impairment, n(%)	226 (10.8%)	135 (6.4%)	108 (4.5%)	72 (2.0%)
Memory impairment, n(%)	157 (7.5%)	116 (5.5%)	145 (6.0%)	106 (3.0%)
Joint pain, n(%)	790 (37.6%)	508 (23.9%)	371 (15.3%)	369 (10.3%)
Overall				
Any symptoms listed above, n(%)	1938 (92.2%)	1496 (70.5%)	993 (41.0%)	904 (25.3%)
With only one symptoms, n(%)	217 (10.3%)	370 (17.4%)	367 (15.2%)	317 (8.9%)
With two symptoms, n(%)	205 (9.8%)	352 (16.6%)	302 (12.5%)	282 (7.9%)
With ≥ 3 symptoms , n(%)	1516 (72.1%)	774 (36.5%)	324 (13.4%)	305 (8.5%)

SUPPLEMENTARY 2C: Long COVID symptoms by age tertile

	All	<50 Years	50-69 Years	>=70 Years	P value
Patients with data, N	4697	2887	1584	226	
Covid symptoms					
Muscle pain, n (%)	130 (2.8%)	84 (2.9%)	43 (2.7%)	3 (1.3%)	0.373
Shortness of breath, n (%)	126 (2.7%)	52 (1.8%)	60 (3.8%)	14 (6.2%)	<0.001
Loss of sense of smell/taste, n (%)	100 (2.1%)	67 (2.3%)	30 (1.9%)	3 (1.3%)	0.537
Diarrhoea, n (%)	43 (0.9%)	28 (1.0%)	15 (0.9%)	0 (0.0%)	0.42
Fatigue, n (%)	410 (8.7%)	223 (7.7%)	158 (10.0%)	29 (12.8%)	0.003
Headaches, n (%)	382 (8.1%)	247 (8.6%)	124 (7.8%)	11 (4.9%)	0.128
Sleeping disorder, n (%)	601 (12.8%)	354 (12.3%)	201 (12.7%)	46 (20.4%)	0.002
Palpitations, n (%)	42 (0.9%)	22 (0.8%)	14 (0.9%)	6 (2.7%)	0.029
Concentration impairment, n (%)	126 (2.7%)	43 (1.5%)	57 (3.6%)	26 (11.5%)	<0.001
Memory impairment, n (%)	143 (3.0%)	57 (2.0%)	60 (3.8%)	26 (11.5%)	<0.001
Joint pain, n (%)	461 (9.8%)	206 (7.1%)	218 (13.8%)	37 (16.4%)	<0.001
Overall					
Any symptoms listed above	1181 (25.1%)	645 (22.3%)	454 (28.7%)	82 (36.3%)	<0.001
With only one symptom	424 (9.0%)	227 (7.9%)	172 (10.9%)	25 (11.1%)	0.002
With two symptoms	352 (7.5%)	208 (7.2%)	127 (8.0%)	17 (7.5%)	0.614
With ≥ 3 symptoms	405 (8.6%)	210 (7.3%)	155 (9.8%)	40 (17.7%)	<0.001
Note: Percentages for symptoms are calculated based on the number of patients with data in each group.					

SUPPLEMENTARY 2D: Long COVID symptoms by ethnic group

	All	Arab	White European	Latin American	South Asian	Other	P value
Patients with data, N	4697	2145	805	398	960	389	
Covid symptoms							
Muscle pain, n (%)	130 (2.8%)	66 (3.1%)	17 (2.1%)	10 (2.5%)	25 (2.6%)	12 (3.1%)	0.665
Shortness of breath, n (%)	126 (2.7%)	35 (1.6%)	37 (4.6%)	6 (1.5%)	37 (3.9%)	11 (2.8%)	<0.001
Loss of smell/taste, n (%)	100 (2.1%)	48 (2.2%)	42 (5.2%)	7 (1.8%)	0 (0.0%)	3 (0.8%)	<0.001
Diarrhoea, n (%)	43 (0.9%)	38 (1.8%)	3 (0.4%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	<0.001
Fatigue, n (%)	410 (8.7%)	237 (11.0%)	60 (7.5%)	22 (5.5%)	79 (8.2%)	12 (3.1%)	<0.001
Headaches, n (%)	382 (8.1%)	331 (15.4%)	23 (2.9%)	6 (1.5%)	17 (1.8%)	5 (1.3%)	<0.001
Sleeping disorder, n (%)	601 (12.8%)	525 (24.5%)	46 (5.7%)	10 (2.5%)	16 (1.7%)	4 (1.0%)	<0.001
Palpitations, n (%)	42 (0.9%)	29 (1.4%)	4 (0.5%)	7 (1.8%)	1 (0.1%)	1 (0.3%)	<0.001
Concentration impairment	126 (2.7%)	51 (2.4%)	51 (6.3%)	13 (3.3%)	7 (0.7%)	4 (1.0%)	<0.001
Memory impairment, n (%)	143 (3.0%)	32 (1.5%)	78 (9.7%)	19 (4.8%)	10 (1.0%)	4 (1.0%)	<0.001
Joint pain, n (%)	461 (9.8%)	378 (17.6%)	64 (8.0%)	6 (1.5%)	7 (0.7%)	6 (1.5%)	<0.001
Overall							
Any symptoms listed above	1181 (25.1%)	775 (36.1%)	197 (24.5%)	59 (14.8%)	113 (11.8%)	37 (9.5%)	<0.001
With only one symptom	424 (9.0%)	210 (9.8%)	96 (11.9%)	33 (8.3%)	60 (6.3%)	25 (6.4%)	<0.001
With two symptoms	352 (7.5%)	271 (12.6%)	34 (4.2%)	13 (3.3%)	28 (2.9%)	6 (1.5%)	<0.001
With ≥ 3 symptoms	405 (8.6%)	294 (13.7%)	67 (8.3%)	13 (3.3%)	25 (2.6%)	6 (1.5%)	<0.001
Note: Percentages for symptoms are calculated based on the number of patients with data in each group.							

SUPPLEMENTARY 2E: Long COVID symptoms by country income level

	All	High income country	Upper middle-income country	Lower middle-income country	P value
Patients with data, N	4697	706	1137	2854	
Covid symptoms					
Muscle pain, n (%)	130 (2.8%)	30 (4.2%)	20 (1.8%)	80 (2.8%)	0.007
Shortness of breath, n (%)	126 (2.7%)	22 (3.1%)	36 (3.2%)	68 (2.4%)	0.285
Loss of sense of smell or taste, n (%)	100 (2.1%)	12 (1.7%)	39 (3.4%)	49 (1.7%)	0.002
Diarrhoea, n (%)	43 (0.9%)	2 (0.3%)	3 (0.3%)	38 (1.3%)	<0.001
Fatigue, n (%)	410 (8.7%)	53 (7.5%)	64 (5.6%)	293 (10.3%)	<0.001
Headaches, n (%)	382 (8.1%)	23 (3.3%)	23 (2.0%)	336 (11.8%)	<0.001
Sleeping disorder, n (%)	601 (12.8%)	22 (3.1%)	49 (4.3%)	530 (18.6%)	<0.001
Palpitations, n (%)	42 (0.9%)	4 (0.6%)	9 (0.8%)	29 (1.0%)	0.48
Concentration impairment, n (%)	126 (2.7%)	16 (2.3%)	56 (4.9%)	54 (1.9%)	<0.001
Memory impairment, n (%)	143 (3.0%)	15 (2.1%)	87 (7.7%)	41 (1.4%)	<0.001
Joint pain, n (%)	461 (9.8%)	15 (2.1%)	66 (5.8%)	380 (13.3%)	<0.001
Overall					
Any symptoms listed above	1181 (25.1%)	102 (14.4%)	229 (20.1%)	850 (29.8%)	<0.001
With only one symptom	424 (9.0%)	55 (7.8%)	119 (10.5%)	250 (8.8%)	0.109
With two symptoms	352 (7.5%)	19 (2.7%)	40 (3.5%)	293 (10.3%)	<0.001
With ≥ 3 symptoms	405 (8.6%)	28 (4.0%)	70 (6.2%)	307 (10.8%)	<0.001
Note: Percentages for symptoms are calculated based on the number of patients with data in each group.					

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Glob Health

SUPPLEMENTARY 3: Baseline table by vaccination status

	Total	Confirmed not vaccinated	Partially vaccinated	Fully vaccinated	P value**
Participants	4678	3444	303	931	
Age (years), mean ± SD	45.9±13.4	44.5±13.2	49.4±13.4	49.8±13.1	<0.001
Males, n (%)	2814 (60.2%)	2020 (58.7%)	200 (66.0%)	594 (63.8%)	0.002
Ethnicity, n (%)					<0.001
- Arab	2144 (45.8%)	1739 (50.5%)	59 (19.5%)	346 (37.2%)	
- White European	796 (17.0%)	592 (17.2%)	39 (12.9%)	165 (17.7%)	
- Latin American	398 (8.5%)	239 (6.9%)	63 (20.8%)	96 (10.3%)	
- South Asian	954 (20.4%)	595 (17.3%)	91 (30.0%)	268 (28.8%)	
- Other Asian	240 (5.1%)	168 (4.9%)	33 (10.9%)	39 (4.2%)	
- Other	145 (3.1%)	111 (3.2%)	17 (5.6%)	17 (1.8%)	
Smoking, n (%)					0.001
- Never	3419 (73.1%)	2492 (72.4%)	235 (77.6%)	692 (74.3%)	
- Former	439 (9.4%)	306 (8.9%)	34 (11.2%)	99 (10.6%)	
- Current (within one year of quitting)	820 (17.5%)	646 (18.8%)	34 (11.2%)	140 (15.0%)	
Diabetes mellitus, n (%)	734 (15.7%)	500 (14.5%)	56 (18.5%)	178 (19.1%)	0.001
Hypertension, n (%)	1072 (22.9%)	711 (20.6%)	88 (29.0%)	273 (29.3%)	<0.001
Dyslipidaemia, n (%)	374 (8.0%)	247 (7.2%)	28 (9.2%)	99 (10.6%)	0.002
CV disease, n (%)	211 (4.5%)	158 (4.6%)	4 (1.3%)	49 (5.3%)	0.015
- Peripheral artery disease, n (%)	36 (0.8%)	23 (0.7%)	2 (0.7%)	11 (1.2%)	0.286
Lung disease, n (%)	308 (6.6%)	213 (6.2%)	24 (7.9%)	71 (7.6%)	0.181
Kidney disease, n (%)	100 (2.1%)	40 (1.2%)	17 (5.6%)	43 (4.6%)	<0.001
Immunosuppressed, n (%)	84 (1.8%)	8 (0.2%)	26 (8.6%)	50 (5.4%)	<0.001
Cancers, n (%)	20 (0.4%)	16 (0.5%)	0 (0.0%)	4 (0.4%)	0.781
Participant type, n (%)					<0.001
- inpatient	1116 (23.9%)	901 (26.2%)	89 (29.4%)	126 (13.5%)	
- outpatient	3562 (76.1%)	2543 (73.8%)	214 (70.6%)	805 (86.5%)	
Treatment, n (%)					0.036
- ASA in ASA trial + Colchicine in COL trial	1170 (25.0%)	839 (24.4%)	88 (29.0%)	243 (26.1%)	
- ASA in ASA trial + Control in COL trial	1172 (25.1%)	859 (24.9%)	63 (20.8%)	250 (26.9%)	
- Control in ASA trial + Colchicine in COL trial	1169 (25.0%)	865 (25.1%)	67 (22.1%)	237 (25.5%)	
- Control in ASA trial + Control in COL trial	1167 (24.9%)	881 (25.6%)	85 (28.1%)	201 (21.6%)	
Note: For continuous variable, ANOVA test was used, for categorical variable, chi-square was used					

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Glob Health

SUPPLEMENTARY 4: Multivariable analysis in inpatients and outpatients

Supplementary Table 4A – Multivariable analysis (inpatients only)

	Overall (N=1119)	With Long Covid (day 180) (N=277)	Without Long Covid (day 180) (N=842)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	p-value*
Age, Mean (sd)	48.7 (13.3)	53.1 (14.2)	47.3 (12.7)	1.03 (1.02- 1.04)	1.02 (1.00- 1.03)	0.009
Male	681 (60.9%)	136 (49.1%)	545 (64.7%)	0.53 (0.40- 0.69)	0.58 (0.41- 0.80)	0.001
Ethnicity						
Arab	186 (16.6%)	106 (38.3%)	80 (9.5%)	*reference*		
White European	61 (5.5%)	23 (8.3%)	38 (4.5%)	0.46 (0.25- 0.83)	0.56 (0.23- 1.38)	0.209
Latin American	118 (10.5%)	37 (13.4%)	81 (9.6%)	0.34 (0.21- 0.56)	0.82 (0.32- 2.08)	0.679
South Asian	513 (45.8%)	90 (32.5%)	423 (50.2%)	0.16 (0.11- 0.23)	0.20 (0.13- 0.30)	<0.001
Other	241 (21.5%)	21 (7.6%)	220 (26.1%)	0.07 (0.04- 0.12)	0.11 (0.06- 0.20)	<0.001
Country income status						
High income country	445 (39.8%)	67 (24.2%)	378 (44.9%)	*reference*		
Upper middle-income country	220 (19.7%)	55 (19.9%)	165 (19.6%)	1.88 (1.26- 2.81)	0.58 (0.27- 1.22)	0.152
Lower middle-income country	454 (40.6%)	155 (56.0%)	299 (35.5%)	2.92 (2.11- 4.04)	1.21 (0.79- 1.85)	0.389
Smoking						
Never	935 (83.6%)	226 (81.6%)	709 (84.2%)	*reference*		
Former	118 (10.5%)	37 (13.4%)	81 (9.6%)	1.43 (0.94- 2.17)	1.66 (1.01- 2.71)	0.044
Current (within one year of quitting)	66 (5.9%)	14 (5.1%)	52 (6.2%)	0.84 (0.46- 1.55)	0.96 (0.49- 1.90)	0.916
Diabetes mellitus	253 (22.6%)	73 (26.4%)	180 (21.4%)	1.32 (0.96- 1.80)	0.94 (0.64- 1.38)	0.747
Hypertension	282 (25.2%)	96 (34.7%)	186 (22.1%)	1.87 (1.39- 2.52)	1.73 (1.18- 2.52)	0.005
Dyslipidemia	86 (7.7%)	25 (9.0%)	61 (7.2%)	1.27 (0.78- 2.07)	1.06 (0.58- 1.93)	0.855
CV disease	31 (2.8%)	11 (4.0%)	20 (2.4%)	1.70 (0.80- 3.59)	0.76 (0.31- 1.85)	0.544
Lung disease	41 (3.7%)	13 (4.7%)	28 (3.3%)	1.43 (0.73- 2.80)	0.93 (0.43- 2.02)	0.861
Kidney disease	7 (0.6%)	1 (0.4%)	6 (0.7%)	-	0.29 (0.03- 2.77)	0.285
Immunosuppressed	4 (0.4%)	0 (0.0%)	4 (0.5%)	-	-	-
Cancer	1 (0.1%)	0 (0.0%)	1 (0.1%)	-	-	-
Vaccination status						
Confirmed not vaccinated	901 (80.5%)	238 (85.9%)	663 (78.7%)	*reference*		
Partially vaccinated	89 (8.0%)	22 (7.9%)	67 (8.0%)	0.91 (0.55- 1.51)	1.21 (0.69- 2.14)	0.507
Fully vaccinated	126 (11.3%)	17 (6.1%)	109 (12.9%)	0.43 (0.26- 0.74)	0.55 (0.31- 1.00)	0.05
Unknown	3 (0.3%)	0 (0.0%)	3 (0.4%)	-	-	-
Treatment						
ASA in ASA trial + Colchicine in COL trial	281 (25.1%)	71 (25.6%)	210 (24.9%)	1.16 (0.79- 1.72)	1.21 (0.78- 1.89)	0.395
ASA in ASA trial + Control in COL trial	287 (25.6%)	69 (24.9%)	218 (25.9%)	1.09 (0.74- 1.61)	1.30 (0.84- 2.02)	0.245
Control in ASA trial + Colchicine in COL trial	280 (25.0%)	76 (27.4%)	204 (24.2%)	1.28 (0.87- 1.89)	1.45 (0.94- 2.25)	0.095
Control in ASA trial + Control in COL trial	271 (24.2%)	61 (22.0%)	210 (24.9%)	*reference*		

Supplementary Table 4B – Multivariable analysis (outpatients only)

	Overall (N=3578)	With Long Covid (day 180) (N=904)	Without Long Covid (day 180) (N=2674)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	p-value*
Age, Mean (sd)	45.0 (13.3)	46.4 (13.6)	44.6 (13.2)	1.01 (1.00- 1.02)	1.03 (1.02- 1.04)	<0.001
Male	2147 (60.0%)	473 (52.3%)	1674 (62.6%)	0.66 (0.56- 0.76)	0.91 (0.75- 1.10)	0.313
Ethnicity						
Arab	1959 (54.8%)	669 (74.0%)	1290 (48.2%)	*reference*		
White European	744 (20.8%)	174 (19.2%)	570 (21.3%)	0.59 (0.48- 0.71)	0.93 (0.44- 1.97)	0.849
Latin American	280 (7.8%)	22 (2.4%)	258 (9.6%)	0.16 (0.11- 0.26)	0.27 (0.11- 0.66)	0.004
South Asian	447 (12.5%)	23 (2.5%)	424 (15.9%)	0.10 (0.07- 0.16)	0.12 (0.07- 0.18)	<0.001
Other	148 (4.1%)	16 (1.8%)	132 (4.9%)	0.23 (0.14- 0.40)	0.30 (0.17- 0.54)	<0.001
Country income status						
High income country	261 (7.3%)	35 (3.9%)	226 (8.5%)	*reference*		
Upper middle-income country	917 (25.6%)	174 (19.2%)	743 (27.8%)	1.51 (1.02- 2.24)	1.16 (0.71- 1.90)	0.564
Lower middle-income country	2400 (67.1%)	695 (76.9%)	1705 (63.8%)	2.63 (1.82- 3.80)	2.10 (1.10- 3.99)	0.024
Smoking						
Never	2497 (69.8%)	674 (74.6%)	1823 (68.2%)	*reference*		
Former	324 (9.1%)	52 (5.8%)	272 (10.2%)	0.52 (0.38- 0.70)	0.52 (0.37- 0.74)	<0.001
Current (within one year of quitting)	757 (21.2%)	178 (19.7%)	579 (21.7%)	0.83 (0.69- 1.01)	0.69 (0.55- 0.86)	0.001
Diabetes mellitus	484 (13.5%)	120 (13.3%)	364 (13.6%)	0.97 (0.78- 1.21)	0.67 (0.51- 0.87)	0.003
Hypertension	793 (22.2%)	222 (24.6%)	571 (21.4%)	1.20 (1.00- 1.43)	1.18 (0.93- 1.50)	0.185
Dyslipidemia	289 (8.1%)	90 (10.0%)	199 (7.4%)	1.38 (1.06- 1.79)	1.14 (0.78- 1.67)	0.493
CV disease	181 (5.1%)	69 (7.6%)	112 (4.2%)	1.89 (1.39- 2.58)	1.32 (0.85- 2.05)	0.217
Lung disease	269 (7.5%)	41 (4.5%)	228 (8.5%)	0.51 (0.36- 0.72)	0.39 (0.27- 0.56)	<0.001
Kidney disease	93 (2.6%)	10 (1.1%)	83 (3.1%)	0.35 (0.18- 0.68)	0.72 (0.33- 1.56)	0.408
Immunosuppressed	80 (2.2%)	4 (0.4%)	76 (2.8%)	0.15 (0.06- 0.42)	-	-
Cancer	19 (0.5%)	6 (0.7%)	13 (0.5%)	1.37 (0.52- 3.61)	0.98 (0.33- 2.89)	0.964
Vaccination status						
Confirmed not vaccinated	2543 (71.1%)	799 (88.4%)	1744 (65.2%)	*reference*		
Partially vaccinated	214 (6.0%)	15 (1.7%)	199 (7.4%)	0.16 (0.10- 0.28)	0.27 (0.15- 0.46)	<0.001
Fully vaccinated	805 (22.5%)	89 (9.8%)	716 (26.8%)	0.27 (0.21- 0.34)	0.31 (0.24- 0.40)	<0.001
Unknown	16 (0.4%)	1 (0.1%)	15 (0.6%)	0.15 (0.02- 1.10)	0.29 (0.04- 2.30)	0.239
Treatment						
ASA in ASA trial + Colchicine in COL trial	894 (25.0%)	216 (23.9%)	678 (25.4%)	0.84 (0.68- 1.04)	0.86 (0.68- 1.08)	0.192
ASA in ASA trial + Control in COL trial	889 (24.8%)	231 (25.6%)	658 (24.6%)	0.93 (0.75- 1.14)	0.91 (0.72- 1.14)	0.406
Control in ASA trial + Colchicine in COL trial	893 (25.0%)	209 (23.1%)	684 (25.6%)	0.81 (0.65- 1.00)	0.80 (0.63- 1.00)	0.053
Control in ASA trial + Control in COL trial	902 (25.2%)	248 (27.4%)	654 (24.5%)	*reference*		